In Figure 2, organ damages treated by HSYA via the NF-κB pathway include brain damages such as ischemia reperfusion-injury, traumatic brain injury, ischemic stroke, and Alzheimer's disease (AD) [29–32]; lung injury such as fetal lung fibroblasts, chronic obstructive pulmonary disease, and acute respiratory distress syndrome [33–35]; cardiac dysfunction [36]; liver ischemia reperfusion-injury [37]; and endometrial inflammation [38]. This evidence concerns the gene NFKB1 and Alzheimer disease.